Vimarsana
Biggest News Aggregation in the World

Page 10 - Appendix Table News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Appendix Table. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Appendix Table Today - Breaking & Trending Today

Characterizing Obesity in a Large Health Care Delivery System - Vimarsana News

Characterizing Obesity in a Large Health Care Delivery System

The prevalence of obesity in the Sutter Health system between 2015 and 2020 was 35%. Differences by race/ethnicity, health insurance, smoking status, and comorbidities were examined.

Source: ajmc.com
At-Home Hemoglobin A1c Testing During COVID-19 Improved Glycemic Control - Vimarsana News

At-Home Hemoglobin A1c Testing During COVID-19 Improved Glycemic Control

Providing at-home hemoglobin A1c test kits increases testing rates and facilitates hemoglobin A1c reduction over time among members of a large commercial health plan with diabetes.

Source: ajmc.com
Safety vs Price in the Generic Drug Market: Metformin - Vimarsana News

Safety vs Price in the Generic Drug Market: Metformin

The generic drug market focuses on price. However, multiple generic metformin drugs have been recalled due to poor drug quality. We examine price and quality after these recalls.

Source: ajmc.com
Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern California - Vimarsana News

Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern California

This analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system.

Source: ajmc.com
Use of Second-Generation Antidiabetic Medication Among a Nationally Representative Sample - Vimarsana News

Use of Second-Generation Antidiabetic Medication Among a Nationally Representative Sample

Among individuals with a diagnosis of type 2 diabetes across the United States, income level, hemoglobin A1c, and comorbidity burden were the primary patient-level drivers of the use of newer antidiabetic agents.

Source: ajmc.com